Abstract | PURPOSE: MATERIALS AND METHODS: Patients with I-PSS (International Prostate Symptom Score) 14 or greater, peak urinary flow rate 4 to 15 ml per second and total prostate volume 30 to 80 ml were randomized 1:1 to a single intraprostatic treatment of onabotulinumtoxinA 200 U or placebo. A single-blind sham procedure followed by a 4-week run-in was included to attempt to minimize any potential placebo effect. Patients who still met eligibility criteria after the run-in entered the double-blind active treatment period. The primary end point was the change from baseline in total I-PSS at week 12. Other end points assessed at weeks 6, 12 and 24 included the change from baseline in total I-PSS, peak urinary flow rate, total prostate volume and post-void residual urine volume. RESULTS: Of 427 patients enrolled 315 were randomized and treated. Decreases from baseline in I-PSS were observed in the onabotulinumtoxinA and placebo groups (-6.3 vs -5.6 points, p <0.001) with no difference between the groups overall or in subgroups. Improvement was observed in the peak urinary flow rate, which was significant only at week 6 compared to placebo. Improvement was significant at all time points in a patient subgroup on stable concurrent α-blockers or 5α-reductase inhibitors during the study. Adverse events were similar in the 2 treatment groups. CONCLUSIONS:
OnabotulinumtoxinA 200 U and placebo improved I-PSS and were well tolerated but no between group difference in efficacy was observed.
|
Authors | Kevin T McVary, Claus G Roehrborn, Emmanuel Chartier-Kastler, Mitchell Efros, Denise Bugarin, Ru Chen, Anand Patel, Cornelia Haag-Molkenteller |
Journal | The Journal of urology
(J Urol)
Vol. 192
Issue 1
Pg. 150-6
(Jul 2014)
ISSN: 1527-3792 [Electronic] United States |
PMID | 24508634
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Acetylcholine Release Inhibitors
- Botulinum Toxins, Type A
|
Topics |
- Acetylcholine Release Inhibitors
(therapeutic use)
- Aged
- Aged, 80 and over
- Botulinum Toxins, Type A
(therapeutic use)
- Double-Blind Method
- Humans
- Lower Urinary Tract Symptoms
(drug therapy, etiology)
- Male
- Middle Aged
- Prostatic Hyperplasia
(complications)
|